Literature DB >> 28267200

Microtubule dynamics and the neurodegenerative triad of Alzheimer's disease: The hidden connection.

Roland Brandt1, Lidia Bakota1.   

Abstract

Alzheimer's disease (AD) is the most common neurodegenerative disorder and is, on a histopathological level, characterized by the presence of extracellular amyloid plaques composed of the protein fragment Aβ, and intracellular neurofibrillary tangles, which contain the microtubule-associated protein tau in a hyperphosphorylated state. In AD defects in microtubule (MT) assembly and organization have also been reported; however, it is unclear whether MT abnormalities have a causal and early role in the disease process or represent a common end point downstream of the neurodegenerative cascade. Recent evidence indicates that microtubule-stabilizing drugs prevent axonopathy in animal models of tauopathies and reverse Aβ-induced loss of synaptic connectivity in an ex vivo model of amyloidosis. This could suggest that MT dysfunction connects some of the degenerative events and provides a useful target to simultaneously prevent several neurodegenerative processes in AD. Here, we describe how changes in the structure and dynamics of MTs are involved in the different aspects of the neurodegenerative triad of AD. We discuss evidence that MTs are affected both by tau-dependent and tau-independent mechanisms but appear to be regulated in a distinct way in different neuronal compartments. We argue that modulation of MT dynamics could be of potential benefit but needs to be precisely controlled in a cell and compartment-specific manner to avoid harmful side effects. This article is part of the series "Beyond Amyloid".
© 2017 International Society for Neurochemistry.

Entities:  

Keywords:  cytoskeleton; dendritic spines; microtubule dynamics; tau protein

Mesh:

Substances:

Year:  2017        PMID: 28267200     DOI: 10.1111/jnc.14011

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  27 in total

Review 1.  Elucidating Tau function and dysfunction in the era of cryo-EM.

Authors:  Guy Lippens; Benoît Gigant
Journal:  J Biol Chem       Date:  2019-05-14       Impact factor: 5.157

Review 2.  Pharmacophore-based models for therapeutic drugs against phosphorylated tau in Alzheimer's disease.

Authors:  Jangampalli Adi Pradeepkiran; Arubala P Reddy; P Hemachandra Reddy
Journal:  Drug Discov Today       Date:  2018-11-16       Impact factor: 7.851

3.  A Synthetic Snake-Venom-Based Tripeptide Protects PC12 Cells from the Neurotoxicity of Acrolein by Improving Axonal Plasticity and Bioenergetics.

Authors:  Carolina P Bernardes; Neife A G Santos; Tassia R Costa; Flavia Sisti; Lilian Amaral; Danilo L Menaldo; Martin K Amstalden; Diego L Ribeiro; Lusânia M G Antunes; Suely Vilela Sampaio; Antonio C Santos
Journal:  Neurotox Res       Date:  2019-10-25       Impact factor: 3.911

Review 4.  Amyloid Oligomers: A Joint Experimental/Computational Perspective on Alzheimer's Disease, Parkinson's Disease, Type II Diabetes, and Amyotrophic Lateral Sclerosis.

Authors:  Phuong H Nguyen; Ayyalusamy Ramamoorthy; Bikash R Sahoo; Jie Zheng; Peter Faller; John E Straub; Laura Dominguez; Joan-Emma Shea; Nikolay V Dokholyan; Alfonso De Simone; Buyong Ma; Ruth Nussinov; Saeed Najafi; Son Tung Ngo; Antoine Loquet; Mara Chiricotto; Pritam Ganguly; James McCarty; Mai Suan Li; Carol Hall; Yiming Wang; Yifat Miller; Simone Melchionna; Birgit Habenstein; Stepan Timr; Jiaxing Chen; Brianna Hnath; Birgit Strodel; Rakez Kayed; Sylvain Lesné; Guanghong Wei; Fabio Sterpone; Andrew J Doig; Philippe Derreumaux
Journal:  Chem Rev       Date:  2021-02-05       Impact factor: 60.622

5.  Glucocorticoid-mediated ER-mitochondria contacts reduce AMPA receptor and mitochondria trafficking into cell terminus via microtubule destabilization.

Authors:  Gee Euhn Choi; Ji Young Oh; Hyun Jik Lee; Chang Woo Chae; Jun Sung Kim; Young Hyun Jung; Ho Jae Han
Journal:  Cell Death Dis       Date:  2018-11-14       Impact factor: 8.469

6.  Modulatory Effects of a Novel Cyclized Peptide in Reducing the Expression of Markers Linked to Alzheimer's Disease.

Authors:  Emanuele Brai; Florian Simon; Antonella Cogoni; Susan A Greenfield
Journal:  Front Neurosci       Date:  2018-06-13       Impact factor: 4.677

7.  Dreaming of a New World Where Alzheimer's Is a Treatable Disorder.

Authors:  Marcella Catania; Giorgio Giaccone; Mario Salmona; Fabrizio Tagliavini; Giuseppe Di Fede
Journal:  Front Aging Neurosci       Date:  2019-11-15       Impact factor: 5.750

Review 8.  Effects of estrogen receptor modulators on cytoskeletal proteins in the central nervous system.

Authors:  Julia J Segura-Uribe; Rodolfo Pinto-Almazán; Angélica Coyoy-Salgado; Claudia E Fuentes-Venado; Christian Guerra-Araiza
Journal:  Neural Regen Res       Date:  2017-08       Impact factor: 5.135

9.  Molecular understanding of label-free second harmonic imaging of microtubules.

Authors:  V Van Steenbergen; W Boesmans; Z Li; Y de Coene; K Vints; P Baatsen; I Dewachter; M Ameloot; K Clays; P Vanden Berghe
Journal:  Nat Commun       Date:  2019-08-06       Impact factor: 14.919

Review 10.  Prevention of Cognitive Decline in Alzheimer's Disease by Novel Antioxidative Supplements.

Authors:  Koh Tadokoro; Yasuyuki Ohta; Haruhiko Inufusa; Alan Foo Nyuk Loon; Koji Abe
Journal:  Int J Mol Sci       Date:  2020-03-13       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.